Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to date Ongoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathway HOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the ...

–     Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician memberHOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman. Dr. Tallman is an internationally renowned clini ...

Annamycin药物 - Annamycin是Moleculin Biotech公司的下一代蒽环类药物，设计为无心毒性，已在美国和欧洲的82名受试者中显示出无心毒性[2] - Annamycin在与Cytarabine联合治疗AML的欧洲临床研究中，2线受试者的初步CRc率达到60%，所有受试者的总体CRc率为39%，持续性正在发展中[2] - Annamycin获得了欧洲药品管理局（EMA）授予AML治疗孤儿药物认定，公司计划在2024年进行关键AML研究，并可能符合加速批准途径[1]

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Conference Call March 25, 2024 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman and CEO Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Vernon Bernardino - H.C. Wainwright Operator Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded. I'd now turn the conf ...

Exhibit 99.1 Moleculin Reports Full Year 2023 Financial Results – Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and webcast Monday, March 25th at 8:30 AM ET – Company to issue separate clinical trial update press release Monday prior to the conference call HOUSTON, March 22, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from to Commission File Number: 001-37758 Moleculin Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4671997 (State or Other Jurisdiction of (I.R.S. Emp ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Jason McCarthy - Maxim Group Jeff Jones - Oppenheimer Operator Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37758 MOLECULIN BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-4671997 (State ...

财务数据和关键指标变化 - 公司第二季度现金余额为3,200万美元,预计可支持到2024年第三季度 [21] - 研发费用较上年同期略有下降,主要是因为公司目前只在进行MB-106和MB-107两个临床试验,而去年还在进行第三个MB-301试验 [22] - 管理费用下降,主要是由于法律费用减少 [22] 各条业务线数据和关键指标变化 - 在软组织肉瘤肺转移的MB-107试验中,26例患者中有73%达到稳定病情,15例进入第二阶段的患者中有67%达到稳定病情 [13] - 在急性髓系白血病的MB-106试验中,6例患者完成了1B阶段剂量递增,其中2例达到完全缓解,完全缓解率为33% [15] 各个市场数据和关键指标变化 - 未提及 公司战略和发展方向及行业竞争 - 公司正在与监管机构就Annamycin的关键临床试验设计进行沟通,为未来的关键临床试验做准备 [24] - 公司相信未来几个季度的临床数据发布将有助于缩小目前股价与公司潜在价值之间的差距 [25] 管理层对经营环境和未来前景的评论 - 管理层对Annamycin在软组织肉瘤和急性髓系白血病适应症的临床数据感到鼓舞,认为这些数据将有助于与监管机构就关键临床试验设计进行沟通 [24] - 管理层表示未来几个季度将有更多临床数据发布,这将有助于投资者更好地认识公司的潜在价值 [25] 问答环节重要的提问和回答 问题1 **Jonathan Aschoff 提问** 询问研发费用是否为临时较低水平 [29] **Jonathan Foster 回答** 研发费用将在第四季度和明年第一季度逐步增加,因为公司需要为未来的临床试验做准备,包括生产另一批Annamycin [31] 问题2 **Jonathan Aschoff 提问** 询问为什么软组织肉瘤试验中包括所有剂量组的稳定病情率高于只包括推荐剂量组的 [34] **Walter Klemp 和 John Paul Waymack 回答** 较早诊断的患者预后较好,而公司试验中的患者平均肺转移诊断时间较长,约20个月,属于较晚期的患者群体 [35][36] 问题3 **Jeff Jones 提问** 询问是否会在学术会议上发表数据,而不仅在季度报告中更新 [40] **Walter Klemp 回答** 公司计划在ASH等重要会议上发表数据,但本次提及的是在季度电话会议中更新数据 [41]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37758 MOLECULIN BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-4671997 (State or O ...